USA flag logo/image

An Official Website of the United States Government

OTHER FUNCTIONS PHASE 0 CARBOPLATIN MICRODOSING DIAGNOSTIC TRIAL.

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
N44CO120048
Solicitation Year:
2012
Solicitation Topic Code:
NCI
Solicitation Number:
Small Business Information
ACCELERATED MEDICAL DIAGNOSTICS, LLC
2121 2ND ST, B-101 DAVIS, CA 95616-5472
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2012
Title: OTHER FUNCTIONS PHASE 0 CARBOPLATIN MICRODOSING DIAGNOSTIC TRIAL.
Agency: HHS
Contract: N44CO120048
Award Amount: $1,499,894.00
 

Abstract:

We developed a technology called PlatinDx that, based upon preclinical data, can potentially identify chemoresistance in lung and bladder cancer patients before they receive carboplatin therapy. PlatinDx utilizes tracing of subtherapeutic microdoses of14C-labeled carboplatin with accelerator mass spectrometry (AMS), which has attomole (10-18 mole) sensitivity for 14C. We hypothesize that DNA damage caused by a single subtoxic microdose of carboplatin can predict patient outcomes such as tumor shrinkage, progression free survival and toxicity. The goal of the project is to test the clinical feasibility of PlatinDx in bladder and lung cancer patients. The PlatinDx data will be compared to ERCC1 expression using the Response Genetics RT-PCR assay as a benchmark. The resulting feasibility data will allow the design of a Pivotal Trial, which is required for FDA clearance and product launch.

Principal Investigator:

Paul Henderson
925-570-1615
HENDERSON48@GMAIL.COM

Business Contact:

Paul Henderson
925-570-1615
HENDERSON48@GMAIL.COM
Small Business Information at Submission:

ACCELERATED MEDICAL DIAGNOSTICS, LLC
ACCELERATED MEDICAL DIAGNOSTICS, LLC DAVIS, CA 95616-5472

EIN/Tax ID: 999999999
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No